中枢神経系用ジェネリック医薬品の世界市場レポート 2025年

中枢神経系用ジェネリック医薬品市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）7.4％で1,254億2,000万米ドルに成長します。予測期間における成長の背景には、メンタルヘルスの啓発に向けた政府のイニシアチブの高まり、ヘルスケア支出の増加、高齢者人口の増加、強力な医薬品パイプラインなどがあります。予測期間における主な動向としては、ウェアラブル技術への投資、中枢神経系開発におけるバイオマーカー、既存薬の改良、医薬品パイプラインへの投資、医薬品製造における3Dプリンティングの利用、研究機関や既存企業との協力関係の確立への注力などが挙げられます。

精神疾患の有病率の増加が予想されることから、ジェネリック中枢神経系（CNS）医薬品市場の成長が見込まれます。精神疾患は、認知、感情調節、行動の重大な障害を特徴とし、しばしば苦痛や機能的制限につながります。ジェネリック中枢神経系（CNS）医薬品は、手頃な価格で利用しやすい治療選択肢を提供することで、メンタルヘルス障害の管理に重要な役割を果たしています。注目すべき例として、2022年11月に英国のHealth and Social Care Information Centreが発表した報告書によると、17～19歳の精神障害の疑い率が上昇しており、2021年の17.4%から2022年には25.7%に増加していることが明らかになった。このことは、精神疾患の罹患率の上昇が市場の成長を牽引していることを裏付けています。

ジェネリック中枢神経系疾患治療薬市場の成長は、ヘルスケア支出の増加によってさらに促進されます。ヘルスケア支出には、特定の期間内にヘルスケア商品およびサービスに費やされる総資源が含まれます。ジェネリック中枢神経系疾患治療薬業界は、メンタルヘルス治療薬へのアクセス性、手頃な価格、革新性の向上を通じて、ヘルスケア支出の増加から利益を得ています。特に、米国メディケア＆メディケイド・サービスセンターは、2022年から2031年にかけての国民医療費（NHE）の平均成長率を5.4%と予測しており、平均GDP成長率（4.6%）を上回っています。成人アメリカ人の60％近くが少なくとも1つの慢性疾患に罹患しているという慢性疾患の増加は、ヘルスケア支出の増加につながり、2030年には年間2兆ドルに達します。したがって、医療費の増加はジェネリック中枢神経系疾患治療薬市場の成長に拍車をかけることになります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界中枢神経系用ジェネリック医薬品 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の中枢神経系用ジェネリック医薬品市場：成長率分析
• 世界の中枢神経系用ジェネリック医薬品市場の実績：規模と成長, 2019-2024
• 世界の中枢神経系用ジェネリック医薬品市場の予測：規模と成長, 2024-2029, 2034F
• 世界中枢神経系用ジェネリック医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の中枢神経系用ジェネリック医薬品市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多発性硬化症（MS）
• 抗精神病薬
• 鎮痛剤
• 抗パーキンソン病薬
• 麻酔薬
• 抗てんかん薬
• 抗うつ薬
• その他のタイプ
• 世界の中枢神経系用ジェネリック医薬品市場薬物分類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブランド医薬品
• ジェネリック医薬品
• 世界の中枢神経系用ジェネリック医薬品市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 神経血管疾患
• 中枢神経系外傷
• メンタルヘルス
• 神経変性疾患
• 感染症
• 中枢神経系がん
• 世界の中枢神経系用ジェネリック医薬品市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• 鼻腔内/吸入
• その他の投与経路
• 世界の中枢神経系用ジェネリック医薬品市場購入方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 市販薬
• 処方薬
• 世界の中枢神経系用ジェネリック医薬品市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の流通チャネル
• 世界の中枢神経系用ジェネリック医薬品市場多発性硬化症（MS）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• インターフェロン
• グラチラマー酢酸塩
• スフィンゴシン-1リン酸受容体モジュレーター
• モノクローナル抗体
• 世界の中枢神経系用ジェネリック医薬品市場、抗精神病薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非定型抗精神病薬
• 典型的な抗精神病薬
• 世界の中枢神経系用ジェネリック医薬品市場、鎮痛剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非オピオイド鎮痛剤
• オピオイド鎮痛剤
• 複合鎮痛剤
• 世界の中枢神経系用ジェネリック医薬品市場、抗パーキンソン病薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドーパミン作動薬
• MAO-B阻害剤
• COMT阻害剤
• 抗コリン薬
• 世界の中枢神経系用ジェネリック医薬品市場麻酔薬の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全身麻酔
• 局所麻酔薬
• 世界の中枢神経系用ジェネリック医薬品市場抗てんかん薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ナトリウムチャネル遮断薬
• GABA増強剤
• グルタミン酸調節剤
• その他のメカニズム
• 世界の中枢神経系用ジェネリック医薬品市場抗うつ薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的セロトニン再取り込み阻害薬（SSRI）
• セロトニン・ノルエピネフリン再取り込み阻害剤（SNRI）
• 三環系抗うつ薬（TCA）
• モノアミン酸化酵素阻害剤（MAOI）
• 非定型抗うつ薬
• 世界の中枢神経系用ジェネリック医薬品市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 認知機能向上剤
• 抗不安薬
• 睡眠補助剤

第7章 地域別・国別分析

• 世界の中枢神経系用ジェネリック医薬品市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の中枢神経系用ジェネリック医薬品市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 中枢神経系用ジェネリック医薬品市場：競合情勢
• 中枢神経系用ジェネリック医薬品市場：企業プロファイル
  • Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • UCB Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi
• Pfizer Inc.
• Merck KGaA
• Sumitomo Dainippon Pharma
• AbbVie
• Recipharm AB
• Neuraxpharm
• Sun Pharmaceutical limited
• Ranbaxy Laboratories
• Merz Pharma GmbH & Co. KGaAare
• AstraZeneca
• Apotex
• Gilead Sciences
• Bayer
• GlaxoSmithKline

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 中枢神経系用ジェネリック医薬品市場2029：新たな機会を提供する国
• 中枢神経系用ジェネリック医薬品市場2029：新たな機会を提供するセグメント
• 中枢神経系用ジェネリック医薬品市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Generic central nervous system (CNS) drugs are medications that impact the central nervous system by slowing down brain activity. They are utilized in the treatment of conditions such as seizures, anxiety, panic attacks, and insomnia.

The major types of generic central nervous system drugs include anti-psychotic, analgesics, anti-parkinson drugs, anesthetics, anti-epileptics, anti-depressants, and others. Antipsychotics, also known as neuroleptics, are a class of medications primarily employed to manage symptoms associated with psychotic disorders such as schizophrenia and bipolar disorder. These drugs are categorized as branded or generic, and their administration routes include oral, intravenous, intranasal/inhalation, and others. They are used to address various diseases such as neurovascular diseases, CNS trauma, mental health conditions, neurodegenerative diseases, infectious diseases, and CNS cancer. The mode of purchase includes over-the-counter drugs and prescription-based drugs, and these drugs are distributed through various channels such as hospital pharmacies, retail pharmacies, and others.

The generic central nervous system drugs market research report is one of a series of new reports from The Business Research Company that provides generic central nervous system drugs market statistics, including generic central nervous system drugs industry global market size, regional shares, competitors with a generic central nervous system drugs market share, detailed generic central nervous system drugs market segments, market trends and opportunities, and any further data you may need to thrive in the generic central nervous system drugs industry. This generic central nervous system drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The generic central nervous system drugs market size has grown strongly in recent years. It will grow from $88.43 billion in 2024 to $94.38 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to from increasing number of surgeries, strong growth in emerging markets, an increase in pharmaceutical R&D, geriatric population, and increased healthcare expenditure.

The generic central nervous system drugs market size is expected to see strong growth in the next few years. It will grow to $125.42 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to growing government initiatives for mental health awareness, a rise in healthcare expenditure, an increasing geriatric population, and a strong pipeline of drugs. Major trends in the forecast period include investing in wearable technology, biomarkers in CNS development, modifying existing drugs, investing in drug pipeline, using 3D printing for drug manufacturing, and focusing on establishing collaborations with research institutions and established companies.

The anticipated increase in the prevalence of mental health disorders is set to drive the growth of the generic central nervous system (CNS) drug market. Mental health disorders, characterized by significant impairment in cognition, emotional regulation, or behavior, often lead to distress and functional limitations. Generic CNS drugs play a vital role in managing mental health disorders by offering affordable and accessible treatment options. A noteworthy example is the report from the UK's Health and Social Care Information Centre in November 2022, revealing a rise in the suspected mental disorder rate among 17- to 19-year-olds, increasing from 17.4% in 2021 to 25.7% in 2022. This underscores the market's growth driven by the escalating incidence of mental health disorders.

The growth of the generic CNS drug market is further propelled by the increasing expenditure on healthcare. Healthcare expenditure encompasses the total resources spent on healthcare goods and services within a specific timeframe. The generic CNS drug industry benefits from higher healthcare spending through improved accessibility, affordability, and innovation in mental health treatment drugs. Notably, the US-based Centers for Medicare & Medicaid Services projects average National Health Expenditures (NHE) growth of 5.4%, exceeding average GDP growth (4.6%) between 2022 and 2031. The rising prevalence of chronic diseases, with almost 60% of adult Americans having at least one chronic disease, contributes to increased healthcare spending, reaching $2 trillion annually by 2030. Thus, the escalating healthcare expenditure is poised to fuel the growth of the generic CNS drug market.

A noteworthy trend in the generic CNS drug market involves major companies focusing on biosimilars for CNS conditions. The development and approval of biosimilars for biologic drugs used in CNS disorders offer cost-effective alternatives to branded biologics. Sandoz, a Switzerland-based pharmaceutical company, launched natalizumab-sztn in October 2023, marking the first biosimilar to treat relapsing forms of multiple sclerosis (MS). This biosimilar provides a more economical option for patients with MS, a chronic autoimmune disease affecting the central nervous system. Such developments underscore the industry trend of introducing biosimilars to address unmet medical needs in CNS disorders.

In November 2022, Avenue Therapeutics, a US-based specialty pharmaceutical company, acquired Baergic Bio, a biopharmaceutical company dedicated to creating innovative therapies for CNS diseases. This acquisition positions Avenue as a leader in developing medications that address unmet medical needs in the CNS field, showcasing the market's strategic partnerships and acquisitions.

Major companies operating in the generic central nervous system drugs market include Biogen Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Novartis AG, UCB, Sanofi, Pfizer Inc., Merck KGaA, Sumitomo Dainippon Pharma, AbbVie, Recipharm AB, Neuraxpharm, Sun Pharmaceutical limited, Ranbaxy Laboratories, Merz Pharma GmbH & Co. KGaAare, AstraZeneca, Apotex, Gilead Sciences, Bayer, GlaxoSmithKline, Amgen, Abbott Laboratories, Janssen Pharmaceutica, Teva Canada, Accord Healthcare Inc., Acerus Pharmaceuticals Corporation, Amgen, EMS Pharma, Hypermarcas, Eurofarma, Teuto Brasileiro, Biolab Farmaceutica, Cristalia, Uniao Quimica, Boehringer Ingelheim, Eli Lilly and Company, Adcock Ingram

North America was the largest region in the generic central nervous system drugs market in 2024. The regions covered in the generic central nervous system drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the generic central nervous system drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The generic central nervous system drugs market consists of sales of sedatives, tranquilizers, and hypnotics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Generic Central Nervous System Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on generic central nervous system drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for generic central nervous system drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The generic central nervous system drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types
• 2) By Drug Classification: Branded Drugs, Generic Drugs
• 3) By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer
• 4) By Route Of Administration: Oral, Intravenous, Intranasal Or Inhalation, Other Route Of Administrations
• 5) By Mode Of Purchase: Over-The-counter drugs, Prescription-Based Drugs
• 6) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
• Subsegments:
• 1) By Multiple Sclerosis (MS): Interferons; Glatiramer Acetate; Sphingosine-1 Phosphate Receptor Modulators; Monoclonal Antibodies
• 2) By Anti-Psychotic: Atypical Antipsychotics; Typical Antipsychotics
• 3) By Analgesics: Non-Opioid Analgesics; Opioid Analgesics; Combination Analgesics
• 4) By Anti-Parkinson Drugs: Dopamine Agonists; MAO-B Inhibitors; COMT Inhibitors; Anticholinergics
• 5) By Anesthetics: General Anesthetics; Local Anesthetics
• 6) By Anti-Epileptics: Sodium Channel Blockers; GABA Enhancers; Glutamate Modulators; Other Mechanisms
• 7) By Anti-Depressants: Selective Serotonin Reuptake Inhibitors (SSRIs); Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs); Tricyclic Antidepressants (TCAs); Monoamine Oxidase Inhibitors (MAOIs); Atypical Antidepressants
• 8) By Other Types: Cognitive Enhancers; Anxiolytics; Sleep Aids
• Companies Mentioned: Biogen Inc.; Johnson & Johnson; Hoffmann-La Roche Ltd; Novartis AG; UCB
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Generic Central Nervous System Drugs Market Characteristics

3. Generic Central Nervous System Drugs Market Trends And Strategies

4. Generic Central Nervous System Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Generic Central Nervous System Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Generic Central Nervous System Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Generic Central Nervous System Drugs Market Growth Rate Analysis
• 5.4. Global Generic Central Nervous System Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Generic Central Nervous System Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Generic Central Nervous System Drugs Total Addressable Market (TAM)

6. Generic Central Nervous System Drugs Market Segmentation

• 6.1. Global Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Multiple Sclerosis (MS)
• Anti-Psychotic
• Analgesics
• Anti-Parkinson Drugs
• Anesthetics
• Anti-Epileptics
• Anti-Depressants
• Other Types
• 6.2. Global Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded Drugs
• Generic Drugs
• 6.3. Global Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neurovascular Diseases
• CNS Trauma
• Mental Health
• Neurodegenerative Diseases
• Infectious Diseases
• CNS Cancer
• 6.4. Global Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Intranasal/ Inhalation
• Other Route Of Administrations
• 6.5. Global Generic Central Nervous System Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Over-the-counter drugs
• Prescription-Based Drugs
• 6.6. Global Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• 6.7. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Multiple Sclerosis (MS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interferons
• Glatiramer Acetate
• Sphingosine-1 Phosphate Receptor Modulators
• Monoclonal Antibodies
• 6.8. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Psychotic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atypical Antipsychotics
• Typical Antipsychotics
• 6.9. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Analgesics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Opioid Analgesics
• Opioid Analgesics
• Combination Analgesics
• 6.10. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Parkinson Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dopamine Agonists
• MAO-B Inhibitors
• COMT Inhibitors
• Anticholinergics
• 6.11. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anesthetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• General Anesthetics
• Local Anesthetics
• 6.12. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Epileptics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sodium Channel Blockers
• GABA Enhancers
• Glutamate Modulators
• Other Mechanisms
• 6.13. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Depressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Tricyclic Antidepressants (TCAs)
• Monoamine Oxidase Inhibitors (MAOIs)
• Atypical Antidepressants
• 6.14. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cognitive Enhancers
• Anxiolytics
• Sleep Aids

7. Generic Central Nervous System Drugs Market Regional And Country Analysis

• 7.1. Global Generic Central Nervous System Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Generic Central Nervous System Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Generic Central Nervous System Drugs Market

• 8.1. Asia-Pacific Generic Central Nervous System Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Generic Central Nervous System Drugs Market

• 9.1. China Generic Central Nervous System Drugs Market Overview
• 9.2. China Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Generic Central Nervous System Drugs Market

• 10.1. India Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Generic Central Nervous System Drugs Market

• 11.1. Japan Generic Central Nervous System Drugs Market Overview
• 11.2. Japan Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Generic Central Nervous System Drugs Market

• 12.1. Australia Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Generic Central Nervous System Drugs Market

• 13.1. Indonesia Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Generic Central Nervous System Drugs Market

• 14.1. South Korea Generic Central Nervous System Drugs Market Overview
• 14.2. South Korea Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Generic Central Nervous System Drugs Market

• 15.1. Western Europe Generic Central Nervous System Drugs Market Overview
• 15.2. Western Europe Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Generic Central Nervous System Drugs Market

• 16.1. UK Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Generic Central Nervous System Drugs Market

• 17.1. Germany Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Generic Central Nervous System Drugs Market

• 18.1. France Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Generic Central Nervous System Drugs Market

• 19.1. Italy Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Generic Central Nervous System Drugs Market

• 20.1. Spain Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Generic Central Nervous System Drugs Market

• 21.1. Eastern Europe Generic Central Nervous System Drugs Market Overview
• 21.2. Eastern Europe Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Generic Central Nervous System Drugs Market

• 22.1. Russia Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Generic Central Nervous System Drugs Market

• 23.1. North America Generic Central Nervous System Drugs Market Overview
• 23.2. North America Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Generic Central Nervous System Drugs Market

• 24.1. USA Generic Central Nervous System Drugs Market Overview
• 24.2. USA Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Generic Central Nervous System Drugs Market

• 25.1. Canada Generic Central Nervous System Drugs Market Overview
• 25.2. Canada Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Generic Central Nervous System Drugs Market

• 26.1. South America Generic Central Nervous System Drugs Market Overview
• 26.2. South America Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Generic Central Nervous System Drugs Market

• 27.1. Brazil Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Generic Central Nervous System Drugs Market

• 28.1. Middle East Generic Central Nervous System Drugs Market Overview
• 28.2. Middle East Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Generic Central Nervous System Drugs Market

• 29.1. Africa Generic Central Nervous System Drugs Market Overview
• 29.2. Africa Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Generic Central Nervous System Drugs Market Competitive Landscape And Company Profiles

• 30.1. Generic Central Nervous System Drugs Market Competitive Landscape
• 30.2. Generic Central Nervous System Drugs Market Company Profiles
  • 30.2.1. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. UCB Overview, Products and Services, Strategy and Financial Analysis

31. Generic Central Nervous System Drugs Market Other Major And Innovative Companies

• 31.1. Sanofi
• 31.2. Pfizer Inc.
• 31.3. Merck KGaA
• 31.4. Sumitomo Dainippon Pharma
• 31.5. AbbVie
• 31.6. Recipharm AB
• 31.7. Neuraxpharm
• 31.8. Sun Pharmaceutical limited
• 31.9. Ranbaxy Laboratories
• 31.10. Merz Pharma GmbH & Co. KGaAare
• 31.11. AstraZeneca
• 31.12. Apotex
• 31.13. Gilead Sciences
• 31.14. Bayer
• 31.15. GlaxoSmithKline

32. Global Generic Central Nervous System Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Generic Central Nervous System Drugs Market

34. Recent Developments In The Generic Central Nervous System Drugs Market

35. Generic Central Nervous System Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Generic Central Nervous System Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Generic Central Nervous System Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Generic Central Nervous System Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer